TTOO - T2 Biosystems, Inc.
| Previous Close | 1.1600 |
| Open | 1.1400 |
| Bid | 1.0500 x 4000 |
| Ask | 1.1900 x 1800 |
| Day's Range | 1.1300 - 1.1800 |
| 52 Week Range | 0.5200 - 5.3800 |
| Volume | 386,767 |
| Avg. Volume | 728,153 |
| Market Cap | 54M |
| Beta (5Y Monthly) | 1.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3490 |
| Earnings Date | Nov 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.41 |
- GlobeNewswire
T2 Biosystems Reports Granting of Inducement Awards
T2 Biosystems, Inc. (TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on December 4, 2019 it issued inducement awards to two new employees. The inducement awards consist of non-qualified stock options to purchase 8,500 shares of T2 Biosystems common stock and have a ten-year term. The exercise price of the options is $1.22, which was the per-share closing price of T2 Biosystems common stock on the Nasdaq Capital Market on December 4, 2019.
- Thomson Reuters StreetEvents
Edited Transcript of TTOO earnings conference call or presentation 12-Nov-19 1:30pm GMT
Q3 2019 T2 Biosystems Inc Earnings Call
- GlobeNewswire
T2 Biosystems Announces Granting of CE-Mark for T2Resistance™ Panel
T2 Biosystems, Inc. (TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, and CARB-X, a global non-profit partnership dedicated to accelerating R&D innovation to address the rising global threat of drug-resistant bacteria, today announced the granting of a CE-Mark to the T2Resistance™ Panel. With CE-Mark, T2 Biosystems has met the requirements of the In-Vitro Diagnostics Directive (98/79/EC) and can market the T2Resistance Panel within the European Economic Area (EEA). The T2Resistance Panel identifies 13 of the most serious resistance genes on the antibiotic-resistance threat list published by the Centers for Disease Control and Prevention (CDC), including genes indicating resistance to common empiric antibiotic therapies such as carbapenems, vancomycin, penicillin and more.
- GlobeNewswire
T2 Biosystems to Present at the 13th Annual Canaccord Genuity Medical Technology & Diagnostics Forum
T2 Biosystems, Inc. (TTOO) (the “Company,”“T2,” or “T2 Biosystems”), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that John McDonough, chairman and chief executive officer, and John Sprague, chief financial officer, are scheduled to present at the 13th Annual Canaccord Genuity Medical Technology & Diagnostics Forum. The presentation will be webcast live and available for replay, and may be accessed by visiting the Investors/Events & Presentations section of the Company’s website at www.t2biosystems.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the Company's website for 90 days following the presentation.
- GlobeNewswire
T2 Biosystems Reports Third Quarter 2019 Financial Highlights and Provides Corporate Update
T2 Biosystems, Inc. (TTOO) (the “Company,”“T2,” or “T2 Biosystems”), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today the operating highlights and preliminary financial results for the third quarter ended September 30, 2019. Due to a ransom cyber-attack on the Company’s information technology (“IT”) systems, the Company is reporting full revenue, new contracts and cash flow highlights as a part of this earnings release along with preliminary earnings estimates.
- GlobeNewswire
T2 Biosystems to Share Early Data at the World Anti-Microbial Resistance Congress (November 7-8, 2019)
T2 Biosystems, Inc. (TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that it will be highlighting its portfolio and pipeline of products in a keynote presentation at the World Anti-Microbial Resistance Congress, which will take place in Washington, DC, on November 7 and 8. The Company will participate in two speaking events at the congress. Sandy Estrada, PharmD, BCPS, Vice President of Medical Affairs, will moderate the panel, “Evaluating Novel Diagnostics for Hospital Use and Uptake in the Clinic–Considerations for Cost, Personnel Training, and Microbiologist Collaboration,” on November 7 at 3:55 p.m. Chief Scientific Officer Tom Lowery, Ph.D., will deliver the keynote address, titled, “The Impact of Rapid, Direct-from-blood Diagnostics in Enabling Changes in Clinical Decisions and Improving Outcomes,” on November 8 at 9:25 a.m.
- American City Business Journals
These 36 Mass. firms made Deloitte's Technology Fast 500
Massachusetts is home to 36 of the 500 companies making this year’s ranking, with three local firms making the top 100 — including the No. 2 spot.
- Zacks
Analysts Estimate T2 Biosystems (TTOO) to Report a Decline in Earnings: What to Look Out for
T2 Biosystems (TTOO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
T2 Biosystems Announces 2019 Third Quarter Financial and Operational Results Release and Conference Call Date
LEXINGTON, Mass., Oct. 31, 2019 -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare,.
- Zacks
Earnings Preview: T2 Biosystems (TTOO) Q3 Earnings Expected to Decline
T2 Biosystems (TTOO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Introducing T2 Biosystems (NASDAQ:TTOO), The Stock That Tanked 84%
T2 Biosystems, Inc. (NASDAQ:TTOO) shareholders will doubtless be very grateful to see the share price up 56% in the...
- GlobeNewswire
T2 Biosystems to Showcase Latest Innovations at IDWeek 2019
T2 Biosystems, Inc. (TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that it will showcase its latest rapid diagnostics for the detection of sepsis-causing pathogens, directly from whole blood, at IDWeek 2019 in Washington, D.C. from October 2 to 6. At the conference – which brings together professionals in the infectious disease industry to meet, share experiences and develop collaborations – the Company will host daily in-booth presentations at booth 1026 that will demonstrate the clinical value of its rapid diagnostics through real-world, clinical case studies.
- GlobeNewswire
T2 Biosystems’ T2Resistance™ Panel is Now Available as a Research Use Only (RUO) Test in the U.S.
T2 Biosystems, Inc. (TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that its T2ResistanceTM Panel, which received Breakthrough Device Designation from the Food and Drug Administration (FDA) earlier this year, is now available as a research use only (RUO) test in the United States. The T2Resistance Panel also remains on track to receive CE-Mark for commercial availability in Europe by the end of 2019. The T2Resistance Panel RUO identifies 13 of the most serious resistance genes on the antibiotic-resistance threat list published by the Centers for Disease Control and Prevention (CDC), including genes indicating resistance to common empiric antibiotic therapies such as carbapenems, vancomycin, penicillin and more.
- GlobeNewswire
T2 Biosystems to Present at the 2019 Cantor Global Healthcare Conference
T2 Biosystems, Inc. (TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that John McDonough, chairman and chief executive officer, and John Sprague, chief financial officer, are scheduled to present at the 2019 Cantor Global Healthcare Conference. The presentation will be webcast live and available for replay, and may be accessed by visiting the Investors/Events & Presentations section of the Company’s website at www.t2biosystems.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the Company's website for 90 days following the presentation.
- GlobeNewswire
T2 Biosystems Enters into Distribution Agreement to Expand its Innovative Rapid Diagnostic Technologies to Puerto Rico and the U.S. Virgin Islands
T2 Biosystems, Inc. (TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that it entered into an exclusive distribution agreement that allows the Company to introduce its rapid diagnostic technologies, including the T2Bacteria® and T2Candida® Panels, in Puerto Rico and the U.S. Virgin Islands, which have approximately 64 hospitals that could benefit from T2’s products. “We are proud to announce this distribution agreement with Bionuclear Puerto Rico, which will give us an opportunity to make a positive impact on clinicians and patients in 64 hospitals in the region,” said John McDonough, chairman and chief executive officer at T2 Biosystems. T2 Biosystems is the company behind the T2Bacteria Panel, which was the first in-vitro diagnostic test to receive approval for a New Technology Add-on Payment (NTAP) by the United States Centers for Medicare & Medicaid Services (CMS).
- GlobeNewswire
T2 Biosystems’ T2Resistance™ Panel is First Diagnostic to Graduate from CARB-X Portfolio
T2 Biosystems, Inc. (TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, and CARB-X, a global non-profit partnership dedicated to accelerating early development antibacterial R&D to address the rising global threat of drug-resistant bacteria, announced today that the T2Resistance™ Panel is the first diagnostic to graduate from CARB-X’s portfolio. In 2017, CARB-X awarded T2 Biosystems $2.0 million to support the development of the T2Resistance Panel, designed to detect 13 resistance genes from both gram-positive and gram-negative pathogens directly from a whole-blood specimen, without the need to wait for blood cultures. “Addressing the global superbug crisis requires urgent development of innovative diagnostics, like T2’s technology, as well as new drugs and vaccines.
- TheStreet.com
2 Downtrodden Small Biotechs That Are Showing Signs of Life
T2 Biosystems and Replimune Group have spurted higher in the last couple weeks, with the former doubling in value on encouraging news.
- GlobeNewswire
T2 Biosystems Receives Funding from BARDA to Advance Technology for Diagnosis and Treatment of Bloodstream Infections
T2 Biosystems, Inc. (TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that it has been awarded a milestone-based contract of initial value of $6 million with a potential value of up to $69 million, if all contract options are exercised, from the Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services’ (HHS). The contract will enable a significant expansion of the Company’s current portfolio of diagnostics for sepsis-causing pathogens and antibiotic-resistance genes, which are designed to improve patient outcomes and reduce the growing threat of antimicrobial resistance.
- GlobeNewswire
T2 Biosystems to Host Conference Call to Discuss Awarding of Multi-Million Dollar BARDA Contract
T2 Biosystems, Inc. (TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today it will host a conference call and webcast to discuss the up to $69 million milestone-based contract it was awarded from the Biomedical Advanced Research and Development Authority (BARDA), which will enable a significant expansion of the Company’s current portfolio of diagnostics for sepsis-causing pathogens and antibiotic-resistance genes. Information related to the BARDA contract is available in an 8-K filed with Securities and Exchange Commission today (available here).
- GlobeNewswire
T2 Biosystems Announces Restructuring of CRG Term Loan Agreement
Reducing the minimum revenue targets for 2020 – 2022 to levels that are below the Company’s current financial forecast. For any shortfall to achieving the minimum revenue targets, the Company has the right to pay double the amount of any shortfall as an acceleration of principal payments (unchanged from existing structure). “We continue to be excited by the potential of T2 Biosystems’ direct-from-blood diagnostic technology for the prevention of sepsis and antibacterial resistance, along with future applications under development,” said Luke Düster, partner of CRG.
- GlobeNewswire
T2 Biosystems Awarded Breakthrough Technology Contract with Premier Inc.
T2 Biosystems, Inc. (TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that Premier Inc., a healthcare improvement company, as part of their Technology Breakthroughs program, has awarded the Company a Breakthrough Technology contract. The agreement will allow Premier’s members, including a network of more than 4,000 U.S. hospitals and health systems, to receive special pricing and access to T2 Biosystems’ T2Bacteria® Panel and T2Candida® Panel – groundbreaking technology that can rapidly detect sepsis-causing pathogens in three to five hours instead of days – to foster fast, accurate therapy of bloodstream infections. “Bloodstream infections can lead to sepsis if they are not diagnosed and treated early on, which can be very serious because sepsis is associated with high mortality rates.
